

Micaela M Hernberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2461239/publications.pdf>

Version: 2024-02-01

35
papers

5,872
citations

567281

15
h-index

395702

33
g-index

36
all docs

36
docs citations

36
times ranked

9485
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	27.0	4,795
2	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	7.1	295
3	Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. <i>Melanoma Research</i> , 2019, 29, 561-568.	1.2	164
4	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	1.6	119
5	Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 3770-3776.	1.6	69
6	A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon- α 2a as first line treatment in metastatic melanoma. <i>Melanoma Research</i> , 2010, 20, 318-325.	1.2	55
7	Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. <i>Blood</i> , 2019, 134, 353-362.	1.4	45
8	Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 128-136.	0.8	39
9	Metastatic uveal melanoma: The final frontier. <i>Progress in Retinal and Eye Research</i> , 2022, 90, 101041.	15.5	36
10	Prospective immunohistochemical analysis of <i>BRAF</i> V600E mutation in melanoma. <i>Human Pathology</i> , 2015, 46, 169-175.	2.0	30
11	Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1999, 16, 145-153.	1.1	22
12	Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 981-993.	3.4	22
13	Selective internal radiation therapy (SIRT) as treatment for hepatic metastases of uveal melanoma: a Finnish nation-wide retrospective experience. <i>Acta Oncologica</i> , 2018, 57, 1373-1380.	1.8	19
14	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021, 158, 156-168.	2.8	19
15	Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 717-730.	4.2	18
16	The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma. <i>Melanoma Research</i> , 2004, 14, 493-500.	1.2	13
17	Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10. <i>Blood</i> , 2014, 124, 799-799.	1.4	12
18	The Prognostic Role of Blood Lymphocyte Subset Distribution in Patients With Resected High-risk Primary or Regionally Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2007, 30, 773-779.	2.4	11

#	ARTICLE	IF	CITATIONS
19	Chemoradiotherapy in the treatment of inoperable high-grade osteosarcoma. <i>Medical Oncology</i> , 2011, 28, 1475-1480.	2.5	9
20	Hepatic Ultrasonography Compared With Computed Tomography and Magnetic Resonance Imaging at Diagnosis of Metastatic Uveal Melanoma. <i>American Journal of Ophthalmology</i> , 2020, 216, 156-164.	3.3	8
21	Metastatic uveal melanoma managed with best supportive care. <i>Acta Oncologica</i> , 2021, 60, 135-139.	1.8	8
22	Impact of staging on survival outcomes: a nationwide real-world cohort study of metastatic uveal melanoma. <i>Melanoma Research</i> , 2021, 31, 224-231.	1.2	8
23	BRAF mutation as a prognostic marker for survival in malignant melanoma: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21566-e21566.	1.6	8
24	Limited-duration anti-PD-1 therapy for patients with metastatic melanoma. <i>Acta Oncologica</i> , 2020, 59, 438-443.	1.8	7
25	Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10. <i>Blood</i> , 2016, 128, 1099-1099.	1.4	7
26	Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma. <i>Acta Oncologica</i> , 2020, 59, 310-314.	1.8	5
27	Long-term prognostic value of sentinel lymph node tumor burden in survival of melanoma patients. <i>Acta Oncologica</i> , 2021, 60, 803-807.	1.8	4
28	BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients. <i>Melanoma Research</i> , 2021, 31, 218-223.	1.2	4
29	A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS9106-TPS9106.	1.6	4
30	High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. <i>Translational Oncology</i> , 2022, 15, 101290.	3.7	4
31	Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma. <i>Endocrine Connections</i> , 2022, 11, .	1.9	4
32	Increased incidence of melanoma in children and adolescents in Finland in 1990â€“2014: nationwide re-evaluation of histopathological characteristics. <i>Annals of Medicine</i> , 2022, 54, 244-252.	3.8	4
33	Different expression of BRAFV600E, ALK and PD-L1 in melanoma in children and adolescents: a nationwide retrospective study in Finland in 1990â€“2014. <i>Acta Oncologica</i> , 2021, 60, 165-172.	1.8	3
34	Pelvic sentinel lymph nodes have minimal impact on survival in melanoma patients. <i>BJS Open</i> , 2021, 5, .	1.7	2
35	Cutaneous sarcoidosis after Hodgkin lymphoma. <i>International Journal of Dermatology</i> , 2019, 58, e17-e19.	1.0	0